×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
DARE – dare bioscience, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
DARE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/6
08:00 am
dare
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development
High
Report
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development
1/9
08:00 am
dare
Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference
12/17
08:15 am
dare
Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Low
Report
Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
12/16
08:00 am
dare
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
Medium
Report
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
12/10
08:00 am
dare
Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
Medium
Report
Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
12/4
08:00 am
dare
Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Medium
Report
Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/14
05:10 pm
dare
Form 8-K Dare Bioscience, Inc. For: Feb 13
Low
Report
Form 8-K Dare Bioscience, Inc. For: Feb 13
2/10
08:02 am
dare
Form 8-K Dare Bioscience, Inc. For: Feb 10
Low
Report
Form 8-K Dare Bioscience, Inc. For: Feb 10
1/31
05:34 pm
dare
Form 4 Dare Bioscience, Inc. For: Jan 28 Filed by: Haring-Layton MarDee
Low
Report
Form 4 Dare Bioscience, Inc. For: Jan 28 Filed by: Haring-Layton MarDee
1/31
05:32 pm
dare
Form 4 Dare Bioscience, Inc. For: Jan 28 Filed by: JOHNSON SABRINA MARTUCCI
Low
Report
Form 4 Dare Bioscience, Inc. For: Jan 28 Filed by: JOHNSON SABRINA MARTUCCI
1/13
08:03 am
dare
Form 8-K Dare Bioscience, Inc. For: Jan 13
Low
Report
Form 8-K Dare Bioscience, Inc. For: Jan 13
12/16
08:05 am
dare
Form 8-K Dare Bioscience, Inc. For: Dec 16
Low
Report
Form 8-K Dare Bioscience, Inc. For: Dec 16
11/27
06:02 am
dare
Form EFFECT Dare Bioscience, Inc.
Medium
Report
Form EFFECT Dare Bioscience, Inc.
11/26
05:17 pm
dare
Form 424B3 Dare Bioscience, Inc.
Medium
Report
Form 424B3 Dare Bioscience, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/21
Form SC 13D/A Dare Bioscience, Inc. Filed by: Dare Bioscience, Inc.
19.1%
1/15 Dare Bioscience Inc (NASDAQ: DARE) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 15.1%
10/14 Daré Bioscience to Participate in Two Upcoming Investor Conferences 14.2%
2/6 Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates 13.9%
3/9 Form 3 Dare Bioscience, Inc. For: Mar 06 Filed by: Fair John A 9.8%
4/14 Form SEC STAFF LETTER Dare Bioscience, Inc. 6.4%
5/1 Form S-1 Dare Bioscience, Inc. 4.7%
3/16 Form 8-K Dare Bioscience, Inc. For: Mar 16 4.4%
11/14 Daré Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update 4.2%
8/12 Daré Bioscience Receives QIDP Designation from the FDA for DARE-BV1 for the Treatment of Bacterial Vaginosis 4.1%
1/15 Dare Bioscience Inc (NASDAQ: DARE) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 15.1%
10/14 Daré Bioscience to Participate in Two Upcoming Investor Conferences 14.2%
2/6 Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates 13.9%
3/9 Form 3 Dare Bioscience, Inc. For: Mar 06 Filed by: Fair John A 9.8%
4/14 Form SEC STAFF LETTER Dare Bioscience, Inc. 6.4%
5/1 Form S-1 Dare Bioscience, Inc. 4.7%
3/16 Form 8-K Dare Bioscience, Inc. For: Mar 16 4.4%
11/14 Daré Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update 4.2%
8/12 Daré Bioscience Receives QIDP Designation from the FDA for DARE-BV1 for the Treatment of Bacterial Vaginosis 4.1%
TOP News Decliners
11/21
Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform
-16.7%
4/28 Dare Bioscience Inc (NASDAQ: DARE) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $7.50 price target on the stock. -16.0%
1/30 Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule -14.4%
11/12 Form 10-Q Dare Bioscience, Inc. For: Sep 30 -13.6%
5/8 Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-FRT1, a Potential Therapy for Preterm Birth and Fertility, in Drug Delivery and Translational Research -12.9%
12/18 Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study -12.7%
9/11 Dare Bioscience Inc (NASDAQ: DARE) is now covered by analysts at Maxim Group. They set a "buy" rating and a $3.00 price target on the stock. -12.2%
1/23 Dare Bioscience Inc (NASDAQ: DARE) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -10.6%
4/1 Daré Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene® -10.5%
9/11 Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Pharmaceutics -10.0%
4/28 Dare Bioscience Inc (NASDAQ: DARE) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $7.50 price target on the stock. -16.0%
1/30 Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule -14.4%
11/12 Form 10-Q Dare Bioscience, Inc. For: Sep 30 -13.6%
5/8 Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-FRT1, a Potential Therapy for Preterm Birth and Fertility, in Drug Delivery and Translational Research -12.9%
12/18 Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study -12.7%
9/11 Dare Bioscience Inc (NASDAQ: DARE) is now covered by analysts at Maxim Group. They set a "buy" rating and a $3.00 price target on the stock. -12.2%
1/23 Dare Bioscience Inc (NASDAQ: DARE) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -10.6%
4/1 Daré Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene® -10.5%
9/11 Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Pharmaceutics -10.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: